This is a preview of subscription content, log in via an institution to check access.
Notes
The study was financially supported by an unrestricted front from Janssen-Cilag GmbH.
Reference
Zeidler J, et al. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany. Applied Health Economics and Health Policy : 22 Aug 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0050-0
Rights and permissions
About this article
Cite this article
Paliperidone LAI preferred option in schizophrenia. PharmacoEcon Outcomes News 686, 9 (2013). https://doi.org/10.1007/s40274-013-0692-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0692-z